PET-CT
Combined imaging that shows metabolic activity and anatomical location.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Assess the spread of disease.
- Helps assess response to treatment.
Informs decisions
- Stage and extent of disease.
- Comparison before and after therapy.
How the test is done
A radioactive tracer substance is injected, then a scan is performed after a certain waiting time.
- Sample type
- Non-invasive (tracer injection)
- Estimated result time
- Results can be read the same day or a few days later.
Preparation
- Fast according to instructions
- Blood sugar level information
- Previous examination history
Limitations
- Inflammation or infection may appear active without associated cancer.
- Not available in all cities and requires separate financing.
- Results need to be read in conjunction with other imaging and clinical conditions.
Related
Cancer types
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Liver Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Colorectal Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Stomach Cancer
Subtype
Reason: Memerlukan pemeriksaan
- CAR-T (chimeric antigen receptor T-cell therapy)
Treatment category
Reason: Memerlukan pemeriksaan
- Surgery (oncologic surgery)
Treatment category
Reason: Memerlukan pemeriksaan
- Brain Cancer
Cancer type
Reason: Memerlukan pemeriksaan
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Complete pathway
Relapsed DLBCL and CAR-T
DLBCL lymphoma has relapsed or is not responding to initial treatment. When does CAR-T start to be discussed?
- Lymphoma, including DLBCL subtypeDisease overview and the DLBCL subtype discussion within it.
- CD19 markerThe target that makes CAR-T cell therapy relevant in B-cell lymphoma.
- CD19 positiveCD19 expression on lymphoma cells, assessed before CAR-T is discussed.
- PET-CTImaging commonly requested to assess relapse and treatment response.
- CAR-T therapyHow cell therapy works, the side effects watched for, and where it is delivered.
- Relapsed DLBCL and CAR-T guideWhen CAR-T is discussed, who decides eligibility, and which records to prepare.
A structured summary so treatment-line history and imaging are readable.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.